Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus HYDRO SERP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus HYDRO SERP 25.
DEMI-REGROTON vs HYDRO-SERP "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination